Learn About Hepatic Venoocclusive Disease with Immunodeficiency
MD Anderson
Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia and is rated as an Advanced provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.
MD Anderson
Hagop Kantarjian is an Oncologist and a Hematologist in Houston, Texas. Dr. Kantarjian and is rated as a Distinguished provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.
MD Anderson
Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour and is rated as a Distinguished provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.
Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-related diseases. However, it comes with serious risks, including a condition called graft-versus-host disease (GVHD), where the transplanted cells attack the patient's body. GVHD can occur in about 50% of patients acutely and 35% in a chronic form, potentially affecting organs like th...
Summary: Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030. A major challenge is to optimize the therapies for localized setting, when oxaliplatin-based chemotherapy is the standard, before and after surgical excision. Because in 50% of cases oxalipl...